Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

• Status: Not yet recruiting
• Trial end date: 2025-08-25

Summary

The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD7789 in patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL).

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Parexel